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One of the challenges in cardiovascular population-based CT screening is to secure 
imaging biomarker validity to perform proper risk stratification on one hand, while 
screening large populations at a radiation dose as low as possible on the other 
hand. The aim of this thesis is to determine the feasibility of radiation dose reduced 
cardiovascular population-based CT screening in order to increase the health benefits 
of screening.
PART I - Design of population-based CT screening
The prevalence and disease burden of cardiovascular disease (CVD), chronic 
obstructive pulmonary disease (COPD) and lung cancer is high. Population-based 
low-dose CT screening followed by early treatment for these three diseases (Big-3) 
has high potential  to cure the disease or to delay or to stop progression of the disease. 
In Chapter 2, the current evidence and CT protocols for early detection of the Big-
3 diseases with low dose chest CT are discussed. Imaging biomarkers are analyzed 
on these low dose CT scans: Lung nodule management based on nodule volume 
measurements can be performed, CVD risk stratification based on coronary artery 
calcium (CAC) score is feasible, and quantification of emphysema shows potential 
for early diagnosis of COPD. Currently, quantification of the different imaging 
biomarkers  is based on different scans each optimized and validated for one of these 
specific imaging biomarkers. Although using validated conventional CT protocols for 
the three biomarkers is most convenient, radiation dose may exceed the maximum 
dose for a screening examination (2.3 mSv, with maximum dose of 5 mSv). Multiple 
options for combining the acquisition protocols for quantification of all three imaging 
biomarkers are available [Chapter 2: Figure 4]. However, there is a sublte balance in 
maintaining imaging biomarker validity of the Big-3 protocol and reducing the total 
radiation dose of such an acquisition. Screening for COPD and CVD in addition to 
lung cancer may significantly improve cost-effectiveness of low-dose lung cancer 
screening in the future. Studies are needed to confirm this hypothesis. Eventually, 
smoking cessation remains the most effective measure for decreasing disease burden 
from the Big-3 diseases. 
Nonetheless, before Big-3 screening can be implemented, a prospective randomized 
study that can show the risk and benefit in CVD risk stratification based on CAC 
scoring should be performed. In Chapter 3, the rationale and technical considerations 





detailed protocol that can be implemented for CAC imaging for screening purposes 
is presented. The imaging protocol includes a fixed tube voltage, individually tailored 
tube current setting, mid-diastolic Electrocardiographic (ECG) triggering, fixed field-
of-view, fixed reconstruction kernel, fixed slice thickness, overlapping reconstruction 
and no iterative reconstruction (IR) [Chapter 3: Table 2 and 3]. Analysis of the 
scans should be performed with one type and version of CAC scoring software, by 
dedicated researchers experienced in CAC scoring. Altogether, the protocol results 
in scans with good image quality for evaluating CAC, at a low radiation dose, 
from which reliable CAC scores can be derived and CVD risk stratification can be 
determined. The data management protocol in chapter 3 describes the organization 
of data handling between the coordinating center, participating centers and analyzing 
center [Chapter 3: Figure 2]. The described imaging protocol is optimized for second 
generation dual-source CT (DSCT) and detection of CAC. Before this protocol can be 
used for other CT systems/generations, validation is needed. The described protocols 
and methods were applied in the large-scale population based cardiovascular screening 
trial ROBINSCA. 
Continuous efforts to further optimize the CAC imaging protocol can be valuable to 
provide a cutting-edge imaging protocol to the market when CVD screening has been 
proven ready for wide-scale implementation. A way to optimize the protocol is to use 
the high-pitch spiral mode not only in participants with a low heart rate (≤65 bpm) 
but also in participants with a high heart rate (>65 bpm), to potentially reduce the 
radiation dose. Nevertheless, the use of high-pitch spiral mode in participants with 
high heart rates should first be validated. In Chapter 4, we found that high-pitch spiral 
mode instead of sequential mode can be used for CAC risk stratification in participants 
(n=1,990) with a regular high heart rate, resulting in 48% radiation dose reduction. A 
similar number of zero scores was found for high-pitch spiral and sequential mode 
CAC scanning regardless of the heart rate. The Agatston score was slightly lower based 
on high-pitch spiral mode scanning compared to sequential mode scanning for both 
the low and high heart rate group. However, the difference in Agatston score between 
high-pitch spiral and sequential mode scans was similar for the high heart rate group 
and the reference low heart rate group. Moreover, risk categorization based on the 
Agatston score showed almost perfect agreement for both scan modes in the high 
heart rate group (κ=0.927) and low heart rate group (κ=0.946) [Chapter 4: Table 1 
and 2]. Thus, radiation dose can potentially be halved when the high-pitch spiral mode 
is used instead of the sequential mode in participants with a regular high heart rate. 
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PART II - Dose reduction as a function of imaging biomarker validity
One of the challenges in population-based CT screening is to secure imaging 
biomarker validity to perform proper risk stratification on one hand, while screening 
large populations at radiation dose as low as possible on the other hand. So far, efforts 
for dose reduction were mainly focused on coronary CT angiography and have not 
been systematically implemented for CAC scoring. In Chapter 5, we systematically 
reviewed the dose reduction techniques in CAC imaging for their impact on Agatston 
score and CVD risk stratification. In total, 27 studies were included of which in 81% 
of the studies, the radiation dose was reduced ≥50% with CT dose index (CTDIvol )
ranging from 0.6 to 5.5 mGy [Chapter 5: Figure 2 and 3]. Dose was reduced with tube 
voltage reduction, tube voltage reduction and IR, tube current reduction, tube current 
reduction and IR, and with tin-filter spectral shaping. The different dose reduction 
techniques had varying impact on Agatston scores and CVD risk stratification. Tube 
voltage reduction led to high agreement for Agatston score but with a systematic under- 
or overestimation of the Agatston score even when the HU-threshold was adapted for 
dose reduced protocol of 0.6 to 1.2 mGy [Chapter 5: Table 1]. Contrary to only tube 
voltage reduction, tube voltage reduction with IR showed similar results for Agatston 
score at a radiation dose of 0.4 to 1.6 mGy (Chapter 5: Table 2]. Likewise, studies 
evaluating tube current-optimized and tube current-reduced protocols reported 
similar Agatston scores or a high agreement of Agatston scores [Chapter 5: Table 3]. 
Tube current reduction combined with high IR levels showed an underestimation of 
the Agatston score, whereas low and moderate levels of IR showed similar Agatston 
scores at a radiation dose of 0.8-3.9 mGy [Chapter 5: Table 4]. Spectral shaping with 
tin-filtration resulted in substantial dose reductions in CAC imaging (total dose: 
0.6-1.3 mGy), but resulted in underestimated Agatston scores [Chapter 5: Table 5]. 
Twelve studies reported reclassification rates for CVD risk stratification, of which 
eight studies reported reclassification rates for tube current reduction with IR. Lower 
levels of IR tended to result in less reclassification, but a wide range of reclassification 
was reported: 3% up to 21% across all types of IR. Specific dose reduced protocols, 
including either tube current reduction and IR or spectral shaping with tin filtration, 
that showed low reclassification rates may potentially be used in CAC scanning and in 
future population-based screening for CVD risk stratification.
Any new dose reduced acquisition protocol to be implementable in clinical practice 
should give comparable CVD stratification results as the conventional protocol. 





quantification is examined to warrant the validity of CAC as an imaging biomarker 
for CVD at ultra-low dose CT. On third generation DSCT, radiation dose reduction 
for CAC scanning might be feasible by combining low tube voltages with a modeled 
based iterative reconstruction algorithm at different strengths. In Chapter 6 the CAC 
detectability and score of thirty different combination protocols with tube voltage 
ranging from 70 to 110 kVp and IR levels 1 to 5 were determined in a thoracic phantom 
study and compared to the reference protocol of 120 kVp, 90 ref mAs with filtered-back 
projection (FBP). For protocols that yielded similar detectability and calcium scores as 
the reference protocol, additional scans were acquired at reduced tube currents ranging 
from 18 to 72 mAs. Moreover, additional scans were also acquired for those protocols 
for two larger thoracic phantom sizes. The detectability and  calcium scores decreased 
at increasing IR levels (τb<-0.825, p<0.001) and increasing tube voltage (τb<-0.679, 
p<0.001) [Chapter 6: Figure 2]. The combination of a tube voltage and IR of 90kVp-IR3 
and 100kVp-IR1 resulted in similar Agatston scores as determined by the conventional 
acquisition at 120kV-FBP without the necessity to change the calcium HU threshold 
(p>0.206). For these protocols, lower tube currents did not affect the detectability 
and Agatston score (p>0.206) [Chapter 6: Figure 4]. In addition, by lowering the tube 
current for these protocols, it was feasible to acquire coronary calcium scans of small, 
medium and large patient sizes with similar results for detectability and Agatston score 
with a dose reduction up to 60.6% compared to the reference protocol of 120kVp-FBP 
[Chapter 6: Table 3]. The 100kVp-IR1 protocol with 52-74 ref mAs also showed similar 
results for calcium volume and mass score as the reference protocol for all patient 
sizes. Nevertheless, variability of the Agatston score was slightly higher for the dose 
reduced protocols. Future in vivo studies should demonstrate whether this impacts 
CVD risk stratification or not. 
The dose of chest CT imaging in third generation DSCT can be further reduced by 
spectral shaping of the x-ray beam due to pre-filtration by a tin-filter placed behind 
the x-ray tube. The potential for radiation dose reduction in lung cancer screening 
with this ultra-low dose chest CT was recently shown. Possibly, the advent of ultra-
low-dose CT lung cancer screening may also offer the opportunity to screen at an 
ultra-low-dose for coronary calcifications. In Chapter 7, we analyzed the impact of 
this ultra-low-dose technique on CAC quantification based on three different CAC 
phantoms. Phantom inserts with 100 small and 9 large calcifications, and a moving 
artificial artery with 3 calcifications (speed 0 to 30 mm/s) were placed in a thorax 
phantom simulating different patient sizes. The phantom was scanned in high-pitch 
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spiral mode at tube voltage of 100 kVp with a tin-filter (Sn100 kVp) with ECG-gating, 
and was compared to the reference protocol with tube voltage of 120 kVp with ECG-
gating. We found that the Sn100 kVp scan protocol with standard HU threshold of 
130 HU, resulted in  lower detectability of calcifications (9% versus 12%, p=0.027) and 
lower calcium scores (p<0.008) regardless of coronary movement [Chapter 7: Table 1, 
Figure 2 and 3]. Adaptation of the HU threshold to 117 HU for calcium scoring at 
Sn100 kVp resulted in similar detectability (p=1.000) and Agatston score (p>0.206) 
for small and medium patient size. Besides, the Sn100 kVp protocol led to a major 
decrease in radiation dose of 63% to 73% for, respectively, small to large patient size.
Methods for dose reduction are not limited to setting and techniques available on a 
scanner, but dose reduction can  also be achieved by comparing different types of CT 
systems, while applying a similar CAC protocol. In large multi-center screening trials 
and in follow-up studies, it is often not possible to use exactly the same type of CT 
system. In Chapter 8, we compared CAC quantification between three generations of 
DSCT systems to determine the variability between CT systems. The same three CAC 
phantoms as in the former chapter were used, and were scanned with tube voltage of 
120 kVp, tube current of 90 reference mAs with prospective ECG-gating at sequential 
and high-pitch spiral mode, for, respectively, first and second/third generation DSCT. 
The three DSCT generations had similar detectability of coronary calcifications with 
median (range) detectability of 11(8), 11(4) and 12(2) out of 100 calcifications, for 
first, second and third generation, respectively (p>0.272). Small variations in median 
Agatston score were found across the three DSCT generations, ranging from 0.5 to 
6.1% for the non-moving phantom, while increasing to a maximum median differenc 
of 12.7% for the phantom with the moving artifical artery [Chapter 8:  Figure  3]. 
Contrary, the mass score varied only by 0.5% to a maximum of 5.1%, with no 
significant differences between the generations for the moving coronary artery. 
Likewise, the variability in mass score tended to be lower than in Agatston score for 
all DSCT systems, with lowest Agatston variability for third generation DSCT. Median 
Agatston and mass score differed by no more than 12.7% and 5.6%. This indicates that 
CAC progression can only be concluded if the Agatston and mass score increase above 
this level compared to baseline.
In Chapter 9, the main findings of the results presented in the previous chapters are 
discussed in a broader perspective and recommendations for future studies are given. 





based CT screening is feasible with a standardized and validated imaging biomarker 
protocol. Combining screening protocols, optimizing scan parameters and using latest 
generation of DSCT can significantly reduce radiation dose. Nevertheless, before 
cardiovascular population-based CT screening can be implemented, an imaging 
biomarker profile for CAC is needed to ensure proper use of dose-reduced protocols.
Future results of the ROBINSCA trial and other large population-based studies should 
show whether CT screening for the Big-3 diseases should be implemented.
 

